Valeant Pharma (VRX) Reports Q2 EPS of $1.91
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Gain on early extinguishment of debt: 0
Today's EPS Names:
DTGI, CRMT, MAYS, More
Financial Fact:
Gain on early extinguishment of debt: 0
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) reported Q2 EPS of $1.91, versus $1.34 reported last year. Revenue for the quarter came in at $1.99 billion, versus $1.06 billion reported last year.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
- Micron posts record profit as AI memory demand fuels explosive growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
